BLT Precautionary response completed
Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 5804, Dunedin 9058, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
12 July 2019
Precautionary response completed
During a review of chemical stock at Blis Technologies’ (NZX:BLT) research and
development laboratory at its South Dunedin manufacturing site, staff noted early
deterioration of a container holding a small quantity of a substance used infrequently in basic
research.
Action was taken by staff, in accordance with the company’s protocols, to contact experts to
understand the appropriate handling of the chemical and its disposal. The container has now
been removed from the building for disposal and the site has reopened.
Fire and Emergency New Zealand has confirmed that the risk mitigation steps and actions
were appropriate.
Health and safety is a priority for the Board. In accordance with company protocols, a review
of the incident will be undertaken.
For further information:
Brian Watson
Chief Executive
027 705 9133
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining
innovation with evidence-based research and the highest quality production controls enables the delivery
of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune
support and teeth and gum health. BLIS products are sold throughout New Zealand and in Australia, Asia,
Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PEB — Pacific Edge Limited: Pacific Edge Reports Continued Growth in FY192019-05-28
“Company Announcement 29 May 2019 reimbursement and we expect to see a continued uplift in adoption and sales in FY20. We remain focused on the USA market which offers enormous potential for our company.” The Company’s key objectives for FY20 are as follows: • GLOBAL R…”
- PEB — Pacific Edge Limited: Cxbladder included in the NCCN Bladder Cancer Guidelines2019-07-15
“Company Announcement 15 July 2019 CXBLADDER INCLUDED IN THE LATEST NCCN BLADDER CANCER GUIDELINES IN THE USA Cancer diagnostics company, Pacific Edge (NZX: PEB), advises that Cxbladder has been included in the latest version of the National Comprehensive Cancer Network…”
- PEB — Pacific Edge Limited: Annual Report & Shareholder Letter2019-06-27
“Adoption of Cxbladder and commercial sales are increasing. We remain focused on further accelerating the adoption of Cxbladder by large healthcare organisations in New Zealand and internationally. New Zealand public healthcare providers lead the world in their adoption of C…”